Loading…
Fortress Biotech, Inc. is projected to rise to $3.83 by 2027, a +16% move from its current price of $3.30. FBIO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.19 | $3.30 | $3.41 | -0.04% |
| Jul 14 | $3.14 | $3.30 | $3.46 | -0.07% |
| Jul 15 | $3.11 | $3.30 | $3.50 | -0.11% |
| Jul 16 | $3.08 | $3.30 | $3.53 | -0.14% |
| Jul 17 | $3.05 | $3.29 | $3.56 | -0.18% |
| Jul 18 | $3.03 | $3.29 | $3.58 | -0.21% |
| Jul 19 | $3.00 | $3.29 | $3.61 | -0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.00 | $3.29 | $3.61 | -0.25% |
| Week 2 | $2.89 | $3.28 | $3.74 | -0.50% |
| Week 3 | $2.80 | $3.28 | $3.84 | -0.75% |
| Week 4 | $2.72 | $3.27 | $3.92 | -0.99% |
| Week 5 | $2.66 | $3.26 | $4.00 | -1.24% |
| Week 6 | $2.60 | $3.25 | $4.06 | -1.49% |
| Week 7 | $2.55 | $3.24 | $4.13 | -1.73% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Fortress Biotech, Inc. is a biopharmaceutical company operating in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc.
in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Fortress Biotech, Inc. trades under the symbol FBIO and currently prices at $3.09 per share with a market capitalization of $102.65M, ranking 4216 by market cap. The stock’s current price sits within a broader forecast path that envisions rising average prices over time, with the 2026 avg of $3.09 and a long-run outlook toward $28.57 by 2050.
The forecast also indicates highs reaching $4.08 in 2026 and up to $57.98 in 2050, underscoring an overall bullish tone for the longer horizon.
A major floor 32.7% below — a decisive break under it would weaken the trend.
The nearest floor, 22.1% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 14.7% above — clearing it would confirm fresh momentum.
Key FBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.11 | Buy | $3.16 | Buy |
| MA 10 | $3.04 | Buy | $3.09 | Buy |
| MA 20 | $3.01 | Buy | $3.01 | Buy |
| MA 50 | $2.73 | Buy | $2.86 | Buy |
| MA 100 | $2.81 | Buy | $2.84 | Buy |
| MA 200 | $2.97 | Buy | $2.80 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.24 | Neutral |
| Stoch RSI (14) | 88.36 | Sell |
| CCI (20) | 168.56 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 4.43 | Buy |
| Bollinger %B (20,2) | 0.99 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.55 | Buy |
| Awesome (5,34) | 0.21 | Buy |
| Ultimate (7,14,28) | 67.62 | Neutral |
| Momentum (10) | 0.28 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 3.20 | Buy |
| ADX (14) | 17.65 | Neutral |
| ATR (14) | 0.09 | Info |
The 30-day technical picture is bullish. RSI14 sits at 60. The 50-day simple moving average is $2.63 and the 200-day simple moving average is $2.98. Nearby support is seen at $2.53 and resistance at $3.16, suggesting a tight range around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.22 | $3.30 | $4.33 | 0% | Neutral | |
| $2.98 | $3.83 | $5.26 | +16% | Neutral | |
| $3.28 | $4.38 | $6.30 | +33% | Bullish | |
| $3.09 | $4.25 | $6.32 | +29% | Bullish | |
| $4.04 | $5.70 | $8.73 | +73% | Bullish | |
| $5.29 | $7.67 | $12.04 | +132% | Bullish | |
| $5.26 | $7.80 | $12.53 | +136% | Bullish | |
| $5.74 | $8.69 | $14.25 | +163% | Bullish | |
| $5.82 | $9.00 | $15.04 | +173% | Bullish | |
| $5.72 | $9.03 | $15.36 | +174% | Bullish | |
| $9.11 | $15.77 | $28.83 | +378% | Bullish | |
| $17.35 | $35.42 | $71.85 | +973% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.22 | $3.30 | $3.98 | +0.00% |
| August 2026 | $2.70 | $3.21 | $3.93 | -2.86% |
| September 2026 | $2.66 | $3.19 | $3.97 | -0.35% |
| October 2026 | $2.77 | $3.34 | $4.20 | +4.71% |
| November 2026 | $2.79 | $3.39 | $4.31 | +1.42% |
| December 2026 | $2.76 | $3.38 | $4.33 | -0.28% |
Click any year to see its month-by-month FBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, FBIO is projected to trade between $2.22 and $4.33, averaging $3.30 — a potential gain of 0% from today's $3.30. A consolidation phase looks the most probable path here.
Fortress Biotech, Inc.'s 2027 outlook centres on $3.83, within a $2.98 to $5.26 range. That is up +16% on the projected 2026 average. That marks a +16% change versus current levels. Price action looks broadly range-bound.
By 2028, FBIO could reach as high as $6.30, with a base case around $4.38 and support toward $3.28 — roughly +33% from $3.30. Buyers look set to stay in control over this stretch.
Expect FBIO to range from $3.09 to $6.32 through 2029. The $4.25 average target implies a +29% move from current prices. That is -3% versus the projected 2028 average. Momentum favours further upside here.
The FBIO price prediction for 2030 points to an average of $5.70 (low $4.04, high $8.73) — a potential gain of +73% on today's $3.30. Buyers look set to stay in control over this stretch.
In 2031, FBIO is projected to trade between $5.29 and $12.04, averaging $7.67 — a potential gain of +132% from today's $3.30. That is up +34% on the projected 2030 average. Momentum favours further upside here.
Fortress Biotech, Inc.'s 2032 outlook centres on $7.80, within a $5.26 to $12.53 range. That is up +2% on the projected 2031 average. That marks a +136% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, FBIO could reach as high as $14.25, with a base case around $8.69 and support toward $5.74 — roughly +163% from $3.30. Momentum favours further upside here.
Expect FBIO to range from $5.82 to $15.04 through 2034. The $9.00 average target implies a +173% move from current prices. That is up +4% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The FBIO price prediction for 2035 points to an average of $9.03 (low $5.72, high $15.36) — a potential gain of +174% on today's $3.30. Momentum favours further upside here.
In 2040, FBIO is projected to trade between $9.11 and $28.83, averaging $15.77 — a potential gain of +378% from today's $3.30. That is up +75% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Fortress Biotech, Inc.'s 2050 outlook centres on $35.42, within a $17.35 to $71.85 range. That is up +125% on the projected 2040 average. That marks a +973% change versus current levels. Momentum favours further upside here.
Investing $1,000 in FBIO today (≈ 303.030303 FBIO) could be worth
$10,732.18
+$9,732.18 (+973%) by 2050 · US Dollar
Based on the average projected FBIO price of $35.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FBIOwould be worth at today's price.
$1,000 invested in FBIO on Jul 10, 2025 (≈ 502.51256 FBIO) would be worth
$1,658.29
+$658.29 (+65.8%) today · 1.66× · US Dollar
Based on a FBIO entry price of $1.99 vs. today's $3.3.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.04 | $1,085.53 | +8.6% |
| 1 month ago | $2.77 | $1,191.34 | +19.1% |
| 3 months ago | $2.35 | $1,404.26 | +40.4% |
| 6 months ago | $4.2 | $785.71 | -21.4% |
| 1 year ago | $1.99 | $1,658.29 | +65.8% |
| All time (5.0y) ago | $49.5 | $66.67 | -93.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FBIO forecast.
Our base-case forecast reaches $6.60 around 2031.
Implied market cap at $6.60: $219.25M
The multi-year forecast shows upside potential across years, with 2030 average price of $5.05 and ROI of 63.5%, followed by 2031 average $6.61 and ROI 113.9%, 2032 average $6.71 and ROI 117.2%, 2033 average $7.49 and ROI 142.4%, 2034 average $7.61 and ROI 146.2%, and 2035 average $7.60 with ROI 146.1%. The trajectory continues into 2040 with average $12.73 and ROI 312%, and into 2050 with average $28.57 and ROI 824.4%. All figures are estimates and not guarantees; actual results depend on market conditions and company developments.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $5.05 with a min of $3.57 and a max of $7.74, and a forecasted ROI of 63.5% with sentiment bullish.
The forecast contains bullish signals across multiple years, with average prices rising to $28.57 by 2050 and a maximum ROI of 824.4%. These are estimates, not guarantees.
Yes. The forecast shows a 2031 max of $10.39 and a 2032 max of $10.79, indicating the potential to reach or exceed $10 within the horizon.
The current price is $3.09.
The 2040 average price is $12.73 with a min of $7.35 and a max of $23.29, and the forecasted ROI is 312%.
Fortress Biotech, Inc. Community Discussion
0Share your Fortress Biotech, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.